Insider Cluster (2 insiders) ·Filed May 1, 2026

SYRE

Spyre Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $1.8M total
Actionable Insight • Neutral

This cluster is routine — the dollar value is negligible relative to Spyre's $6.9B market cap. The CMO's derivative exercise is a standard cashless exercise, not a signal. No action warranted. Monitor for any material change in insider selling velocity (e.g., >$10M in a 7-day window) before assigning directional significance.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
SYRE ▲ +43.99% at T+60d
NEUTRAL call ✓ call won +43.99% · α vs SPY +40.92% · entry $69.42 → $99.96
Entry anchored
Apr 30, 03:59 PM ET
via exchange tick
T+1d
-0.42%
call -0.42% · α -0.08%
$69.13
settled 5mo ago
T+5d
+5.30%
call +5.30% · α +2.95%
$73.10
settled 5mo ago
T+20d
+1.61%
call +1.61% · α -3.67%
$70.54
settled 4mo ago
T+60d
+43.99%
call +43.99% · α +40.92%
$99.96
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

CEO and CMO sold a combined $1.85M in open-market sales at ~$69.50, representing 0.027% of Spyre's $6.9B market cap. The CMO also exercised and sold shares from a derivative grant, a routine cashless exercise pattern. The dollar amount is trivial relative to market cap, making this a routine cluster with no material directional signal.

Key Financial Metrics

Direction
selling
Total Value
$1.9M
Insiders
2

Key Facts

  • CEO Turtle Cameron sold 5,300 shares for $369K on May 1, 2026
  • CMO Sloan Sheldon sold 21,306 shares for $1.48M on May 1, 2026
  • CMO also exercised 78,333 derivative shares at $27.46 ($2.15M) and 78,333 at $0 (non-cash award) — these are non-cash events
  • Total open-market sales of $1.85M represent just 0.027% of $6.9B market cap
  • No open-market purchases in the cluster

Financial Impact

Total insider sales of $1.85M, or 0.027% of market cap — immaterial

insider holdingsfloat

Risk Factors

  • Insider selling could accelerate ahead of a catalyst event (e.g., clinical data readout)
  • CEO selling, while small, is the first CEO sale in the recent 30-day window — worth tracking

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SYRE-1777685708871
26 reports for SYRE
Performance horizon
77% Hit rate 10 of 13 directional calls best @ T+60▲ +54.27%Apr 13, 2026
Filters
Rows
Reports for SYRE — sortable, filterable
TypeNow
Sep 4, 2026
28d ago
Insider Cluster
BEARISH ★ 5/10
$88.98 $90.80▼ −2.05%▼ −3.25%$93.19 (−4.73%)
Aug 11, 2026
7w ago
Insider Cluster
BEARISH ★ 5/10
$102.74 $107.82▼ −4.94%▼ −5.35%$93.19 (+9.30%)
Aug 6, 2026
8w ago
Insider Cluster
BEARISH ★ 5/10
$103.42 $101.85▲ +1.52%▲ +2.73%$93.19 (+9.89%)
Jul 3, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$86.63 $98.75▲ +13.99%▲ +13.06%$93.19 (+7.57%)
Jun 27, 2026
13w ago
Insider Cluster
BEARISH ★ 7/10
$90.16 $88.74▲ +1.57%▲ +2.96%$93.19 (−3.36%)
Jun 26, 2026
14w ago
S-3ASR
NEUTRAL ★ 5/10
$90.16 $88.74▼ −1.57%▼ −2.96%$93.19 (+3.36%)
Jun 24, 2026
14w ago
Insider Cluster
BEARISH ★ 7/10
$86.24 $88.89▼ −3.07%▼ −1.37%$93.19 (−8.06%)
Jun 15, 2026
15w ago
8-K
BULLISH ★ 7/10
$83.58 $100.32▲ +20.03%▲ +21.41%$93.19 (+11.50%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$80.79 $88.34▲ +9.35%▲ +8.67%$93.19 (+15.35%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$80.77 $87.49▲ +8.32%▲ +7.89%$93.19 (+15.38%)
Showing 10 of 26

US Market Status

Market Closed — Opens Mon (65h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 2, 2026